BioSenic Investor Relations

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company’s technologies include arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops ArsciCor, an oral medication in Phase III clinical trial and for the treatment for chronic graft-versus-host disease; JTA-004, an intra-articular injectable in Phase III clinical trial to treat osteoarthritic knee pain; ALLOB, an allogeneic differentiated osteoblast product in Phase IIb clinical trial for patients with difficult tibial fractures and lumbar spinal fusion; and ARSCICOP, an oral medication in Phase IIa trial for the treatment of systemic lupus erythematosus, as well as in preclinical trial to treat systemic sclerosis. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.

Read Less